Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 1, 2007

Argenta to Aid CellCentric in Epigenetic Research

  • Argenta Discovery entered into a fee-for-service collaboration with CellCentric. Under the terms of the agreement, scientists from the two companies will exploit Argenta’s expertise to discover inhibitors for two potential epigenetic-related therapeutic targets.

    “Their decision to work with us is based on our contract drug discovery team’s acknowledged expertise in hit identification and assay development,” notes Christopher Ashton, Argenta’s chief executive.

    Will West, CEO of CellCentric adds that Argenta’s know-how in hit identification, assay development, and screening will help advance the company’s knowledge and expertise in epigenetic research.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »